COMPANY PROFILE

TOLREMO therapeutics

Explore full profile

Focused on the discovery and development of small molecules to prevent resistance in cancer therapy

Basel, SwitzerlandFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About TOLREMO therapeutics

TOLREMO Therapeutics is a biotechnology company focused on preventing resistance to cancer therapies. The company operates in the healthcare and pharmaceutical market, primarily serving patients with cancer and healthcare providers. TOLREMO's business model revolves around its proprietary drug discovery and development platform, which identifies novel drug resistance regulators and develops small molecule therapies to target these regulators. These therapies are designed to complement standard cancer treatments, aiming to improve response rates, extend survival times, and enhance the quality of life for patients. The company generates revenue through the development and commercialization of its proprietary therapies, as well as potential partnerships and licensing agreements with other pharmaceutical companies.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Basel, Switzerland
Employees: 16
Open positions: 1
Dealroom signal: 78.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Core AI, Medical Data, Spinout, Gold Track (EIT Health)
Technology: Artificial Intelligence, Big Data
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Sep 2023	$31M	$125M	Pierre Fabre · BioMedVC	↗
SERIES A✓Equity / VC	Jun 2020	$4.3M	$17M	Redalpine · ZKB - Zürcher Kantonalbank · BioMedVC · Altos Ventures	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

TOLREMO therapeutics website traffic

Latest recorded traffic for TOLREMO therapeutics is 2.1K monthly website visits, up 150% over the last three months. TOLREMO therapeutics's team grew 6.7% over the past year.

Latest monthly visits2.1K 3-month web change+150% 1-year team growth+6.7%

Monthly website visitsNov 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational	73	$3.9M	$15M
ILiLoFAI and photonics platform for personalized drug discovery.	London, United Kingdom	Operational
BIBioXplorDeveloping a computational network pharmacology platform to match optimal drug combinations to the right patients	Dublin, Ireland	Operational
NENeuroelectricsDeveloping a unique platform to treat brain dysfunction with cloud-based, personalized neuromodulation	Barcelona, Spain	Operational
OPOptellumDeveloping an artificial intelligence software platform to support clinicians in lung cancer nodule management	Oxford, United Kingdom	Operational
NTNuage TherapeuticsTherapeutics targeting intrinsically disordered proteins for cancer	Barcelona, Spain	Operational
MAMAbSilicoComputational solutions for antibody discovery using Artificial Intelligence and Machine Learning	Tours, France	Operational
TATurbine AISimulation-driven drug discovery company delivering population targeted cancer therapies	Budapest, Hungary	Operational